ENB 106
Alternative Names: ENB-106Latest Information Update: 26 Aug 2024
At a glance
- Originator EnnovaBio
- Class Eye disorder therapies; Hepatoprotectants; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Acute kidney injury; Diabetic macular oedema; Diabetic retinopathy; Non-alcoholic steatohepatitis
Most Recent Events
- 31 Jul 2024 Phase-II/III clinical trials in Acute kidney injury (PO) prior to July 2024 (EnnovaBio pipeline, July 2024)
- 31 Jul 2024 Phase-II/III clinical trials in Diabetic macular oedema (PO) prior to July 2024 (EnnovaBio pipeline, July 2024)
- 31 Jul 2024 Phase-II/III clinical trials in Diabetic retinopathy (PO) prior to July 2024 (EnnovaBio pipeline, July 2024)